AstraZeneca profits rise, but more jobs to go
Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning unveiled a set of financial results for the fourth quarter and full-year 2011, broadly in line with expectations, but also confirmed recent speculation that further large cuts in its workforce would be implemented.
Core operating profit for the full year was down 4% at constant exchange rates (CER) to $13.17 billion. Core earnings per share for the full year increased by 7% at CER to $7.28. Reported EPS leapt 29% at CER to $7.33, benefiting from the sale of Astra Tech and higher intangible impairments in 2010.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze